José María Ruiz Moreno-rekin lankidetzan egindako argitalpenak (14)

2023

  1. A Randomized Controlled Trial of OPT-302, a VEGF-C/D Inhibitor for Neovascular Age-Related Macular Degeneration

    Ophthalmology, Vol. 130, Núm. 6, pp. 588-597

  2. Effectiveness and safety of fluocinolone acetonide intravitreal implant in diabetic macular edema patients considered insufficiently responsive to available therapies (REACT): a prospective, non-randomized, and multicenter study

    International Ophthalmology, Vol. 43, Núm. 12, pp. 4639-4649

2020

  1. Bimonthly, treat-and-extend and as-needed ranibizumab in naïve neovascular age-related macular degeneration patients: 12-month outcomes of a randomized study

    Acta Ophthalmologica, Vol. 98, Núm. 7, pp. e820-e829

  2. Genetic and environmental factors related to the development of myopic maculopathy in Spanish patients

    PloS one, Vol. 15, Núm. 7, pp. e0236071

2016

  1. Casos clínicos en oftalmología: problemas diagnósticos en patología retinocoroidea

    Euromedice

  2. Evaluation of 10 AMD Associated polymorphisms as a cause of choroidal neovascularization in highly myopic eyes

    PLoS ONE, Vol. 11, Núm. 9

2015

  1. Individualized Therapy with Ranibizumab in Wet Age-Related Macular Degeneration

    Journal of Ophthalmology, Vol. 2015

  2. Intravitreal anti-vascular endothelial growth factor therapy for choroidal neovascularization secondary to pathologic myopia six years outcome

    Retina, Vol. 35, Núm. 12, pp. 2450-2456

  3. Treatment of Exudative Age-related Macular Degeneration: Focus on Aflibercept

    Drugs and Aging, Vol. 32, Núm. 10, pp. 797-807

2014

  1. A Delphi study to detect deficiencies and propose actions in real life treatment of neovascular age-related macular degeneration

    Journal of Ophthalmology, Vol. 2014

2013

  1. Spectral-domain optical coherence tomography study of macular structure as prognostic and determining factor for macular hole surgery outcome

    Retina, Vol. 33, Núm. 6, pp. 1117-1122

2012

  1. Three versus one intravitreal bevacizumab injections as initial protocol to treat myopic choroidal neovascularization

    Acta Ophthalmologica

2010

  1. Twelve-month outcome after one intravitreal injection of bevacizumab to treat myopic choroidal neovascularization

    Retina, Vol. 30, Núm. 10, pp. 1609-1615

2006

  1. Photodynamic therapy in subfoveal and juxtafoveal idiopathic and postinflammatory choroidal neovascularization

    Acta Ophthalmologica Scandinavica, Vol. 84, Núm. 6, pp. 743-748